Polymerisation catalysts and systems comprising said catalysts for polymerising carbon dioxide and an epoxide, a lactide and/or lactone, and/or an epoxide and an anhydride. The catalyst is of formula (I):

##STR00001##

Wherein M.sub.1 and M.sub.2 are independently selected from Zn(II), Cr(II), Co(II), Cu(II), Mn(II), Ni(II), Mg(II), Fe(II), Ti(II), V(II), Cr(III)-X, Co(III)-X, Ni(III)-X, Mn(III)-X, Fe(III)-X, Ca(II), Ge(II), AI(III)-X, Ti(III)-X, V(III)-X, Ge(IV)-(X).sub.2 or Ti(IV)-(X).sub.2. R.sub.3A is different from R.sub.3B; and/or at least one occurrence of E.sub.3, E.sub.4, E.sub.5 and E.sub.6 is different to a remaining occurrence of E.sub.3, E.sub.4, E.sub.5 and E.sub.6. A ligand, a process of asymmetric N-substitution of a symmetrical ligand and a process for the reaction of: (i) carbon dioxide with an epoxide; (ii) an epoxide and an anhydride; and/or (iii) a lactide and/or a lactone, in the presence of a catalyst is also described.

The disclosure provides for compounds having immunoproteasome inhibitory activity, and pharmaceutical compositions made thereof. The disclosure further provides for the use of the compounds and compositions in treating various diseases and disorders in a subject that are associated with immunoproteasome activity, including inflammatory disorders, autoimmune disorders, hematological disorders, and neurodegenerative disorders.

The disclosure provides for compounds having immunoproteasome inhibitory activity, and pharmaceutical compositions made thereof. The disclosure further provides for the use of the compounds and compositions in treating various diseases and disorders in a subject that are associated with immunoproteasome activity, including inflammatory disorders, autoimmune disorders, hematological disorders, and neurodegenerative disorders.

The invention provides an anthracene-based organic dye and a preparation method thereof. The organic dye provided by the invention has a structure of formula (I) or formula (II), wherein R.sub.a, R.sub.b, and R.sub.2-1 to R.sub.2-4 are as defined herein. The organic dye provided by the invention is obtained by modifying an anthracene with R.sub.a and R.sub.b or modifying anthracene-based groups decorated with an aryl group or a heteroaryl group with R.sub.a and R.sub.b, thereby the power conversion efficiency of a dye sensitized solar cell is significantly improved when the organic dye prepared according to the present invention is applied in a dye-sensitized solar cell. Furthermore, the preparation method of the organic dye according to the present invention is quite simple together with abundant raw materials and low cost, making it possible to be commercialized.

The invention provides an anthracene-based organic dye and a preparation method thereof. The organic dye provided by the invention has a structure of formula (I) or formula (II), wherein R.sub.a, R.sub.b, and R.sub.2-1 to R.sub.2-4 are as defined herein. The organic dye provided by the invention is obtained by modifying an anthracene with R.sub.a and R.sub.b or modifying anthracene-based groups decorated with an aryl group or a heteroaryl group with R.sub.a and R.sub.b, thereby the power conversion efficiency of a dye sensitized solar cell is significantly improved when the organic dye prepared according to the present invention is applied in a dye-sensitized solar cell. Furthermore, the preparation method of the organic dye according to the present invention is quite simple together with abundant raw materials and low cost, making it possible to be commercialized.

The present invention relates to the field of polymerisation catalysts, and systems comprising said catalysts for polymerising carbon dioxide and an epoxide, a lactide and/or lactone, and/or an epoxide and an anhydride. The catalyst is of formula (I): ##STR00001## Wherein M.sub.1 and M.sub.2 are independently selected from Zn(II), Cr(II), Co(II), Cu(II), Mn(II), Ni(II), Mg(II), Fe(II), Ti(II), V(II), Cr(III)-X, Co(III)-X, Ni(III)-X, Mn(III)-X, Fe(III)-X, Ca(II), Ge(II), Al(III)-X, Ti(III)-X, V(III)-X, Ge(IV)-(X).sub.2 or Ti(IV)-(X).sub.2. R.sub.3A is different from R.sub.3B; and/or at least one occurrence of E.sub.3, E.sub.4, E.sub.5 and E.sub.6 is different to a remaining occurrence of E.sub.3, E.sub.4, E.sub.5 and E.sub.6. A ligand, a process of asymmetric N-substitution of a symmetrical ligand and a process for the reaction of: (i) carbon dioxide with an epoxide; (ii) an epoxide and an anhydride; and/or (iii) a lactide and/or a lactone, in the presence of a catalyst is also described.

The present invention relates to the field of polymerisation catalysts, and systems comprising said catalysts for polymerising carbon dioxide and an epoxide, a lactide and/or lactone, and/or an epoxide and an anhydride. The catalyst is of formula (I): ##STR00001## Wherein M.sub.1 and M.sub.2 are independently selected from Zn(II), Cr(II), Co(II), Cu(II), Mn(II), Ni(II), Mg(II), Fe(II), Ti(II), V(II), Cr(III)-X, Co(III)-X, Ni(III)-X, Mn(III)-X, Fe(III)-X, Ca(II), Ge(II), Al(III)-X, Ti(III)-X, V(III)-X, Ge(IV)-(X).sub.2 or Ti(IV)-(X).sub.2. R.sub.3A is different from R.sub.3B; and/or at least one occurrence of E.sub.3, E.sub.4, E.sub.5 and E.sub.6 is different to a remaining occurrence of E.sub.3, E.sub.4, E.sub.5 and E.sub.6. A ligand, a process of asymmetric N-substitution of a symmetrical ligand and a process for the reaction of: (i) carbon dioxide with an epoxide; (ii) an epoxide and an anhydride; and/or (iii) a lactide and/or a lactone, in the presence of a catalyst is also described.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:

##STR00001##

which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:

##STR00001##

which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

The invention provides an anthracene-based organic dye and a preparation method thereof. The organic dye provided by the invention has a structure of formula (I) or formula (II), wherein R.sub.a, R.sub.b, and R.sub.2-1 to R.sub.2-4 are as defined herein. The organic dye provided by the invention is obtained by modifying an anthracene with R.sub.a and R.sub.b or modifying anthracene-based groups decorated with an aryl group or a heteroaryl group with R.sub.a and R.sub.b, thereby the power conversion efficiency of a dye sensitized solar cell is significantly improved when the organic dye prepared according to the present invention is applied in a dye-sensitized solar cell. Furthermore, the preparation method of the organic dye according to the present invention is quite simple together with abundant raw materials and low cost, making it possible to be commercialized.